Profile data is unavailable for this security.
About the company
Theriva Biologics, Inc. is a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need. It is advancing a new oncolytic adenovirus platform. Its candidates are VCN-01, SYN-004 (ribaxamase) and SYN-020. VCN-01 is an oncolytic adenovirus designed to replicate selectively and aggressively within tumor cells, and to degrade the tumor stroma barrier that serves as a significant physical and immunosuppressive barrier to cancer treatment. SYN-004 (ribaxamase) is designed to degrade certain commonly used intravenous beta-lactam antibiotics within the gastrointestinal (GI) tract to prevent microbiome damage. SYN-020 is a recombinant oral formulation of the enzyme intestinal alkaline phosphatase produced under current good manufacturing practice conditions and intended to treat both local GI and systemic diseases. Its research programs include VCN-11 Albumin Shield Technology and SYN-006, SYN-007, other oncolytic virus.
- Revenue in USD (TTM)0.00
- Net income in USD-22.27m
- Incorporated2008
- Employees21.00
- LocationTheriva Biologics Inc9605 Medical Center Drive, Suite 270ROCKVILLE 20850United StatesUSA
- Phone+1 (734) 332-7800
- Fax+1 (734) 332-7878
- Websitehttps://therivabio.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Biostax Corp | 0.00 | -1.51m | 3.27m | -- | -- | -- | -- | -- | -0.0181 | -0.0181 | 0.00 | -0.0633 | 0.00 | -- | -- | -- | -395.44 | -81.51 | -- | -- | -- | -- | -- | -- | -- | -4.04 | -- | -- | -- | -- | 53.32 | -- | -- | -- |
| Lipella Pharmaceuticals Inc | 507.20k | -4.14m | 3.27m | 5.00 | -- | 1.82 | -- | 6.45 | -0.6188 | -0.6188 | 0.074 | 0.224 | 0.1788 | -- | 16.01 | 101,440.00 | -146.02 | -- | -169.27 | -- | -- | -- | -816.72 | -- | -- | -- | 0.00 | -- | 144.15 | -- | -77.81 | -- | -- | -- |
| NovaBay Pharmaceuticals Inc | 12.02m | -15.98m | 3.34m | 24.00 | -- | -- | -- | 0.2778 | -65.73 | -65.91 | 21.94 | -0.4577 | 1.21 | 2.29 | 7.59 | 500,958.30 | -105.75 | -61.51 | -205.52 | -83.89 | 58.55 | 59.99 | -87.67 | -86.47 | 0.4302 | -- | 8.81 | -- | 2.24 | 3.32 | -2.66 | -- | -15.46 | -- |
| Windtree Therapeutics Inc | 0.00 | -11.38m | 3.39m | 15.00 | -- | 0.1559 | -- | -- | -0.7463 | -0.7463 | 0.00 | 17.65 | 0.00 | -- | -- | 0.00 | -32.86 | -44.51 | -40.15 | -48.38 | -- | -- | -- | -94,533.34 | -- | -- | 0.1612 | -- | -- | -- | 48.25 | -- | -- | -- |
| Chromocell Therapeutics Corp | 0.00 | -8.98m | 3.45m | 4.00 | -- | 3.06 | -- | -- | -1.66 | -1.66 | 0.00 | 0.196 | 0.00 | -- | -- | 0.00 | -440.01 | -- | -- | -- | -- | -- | -- | -- | -- | -7.20 | 0.00 | -- | -- | -- | -200.20 | -- | -- | -- |
| Theriva Biologics Inc | 0.00 | -22.27m | 3.50m | 21.00 | -- | 1.33 | -- | -- | -1.25 | -1.25 | 0.00 | 1.23 | 0.00 | -- | -- | 0.00 | -41.30 | -36.95 | -48.49 | -40.16 | -- | -- | -- | -- | -- | -- | 0.0056 | -- | -- | -- | 8.37 | -- | 95.91 | -- |
| ENDRA Life Sciences Inc | 0.00 | -9.57m | 3.50m | 21.00 | -- | 0.0311 | -- | -- | -45.63 | -45.63 | 0.00 | 6.21 | 0.00 | -- | -- | 0.00 | -97.17 | -132.00 | -117.34 | -157.28 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 23.67 | -- | -19.46 | -- |
| TNF Pharmaceuticals Inc | 0.00 | -7.07m | 3.56m | 9.00 | -- | 0.153 | -- | -- | -5.53 | -5.53 | 0.00 | 10.28 | 0.00 | -- | -- | 0.00 | -25.59 | -76.20 | -31.13 | -84.38 | -- | 7.64 | -- | -4,290.96 | -- | -- | 0.00 | -- | -- | -- | 49.15 | -- | -- | -- |
| Hepion Pharmaceuticals Inc | 0.00 | -28.37m | 3.61m | 22.00 | -- | 1.93 | -- | -- | -6.49 | -6.49 | 0.00 | 0.6142 | 0.00 | -- | -- | 0.00 | -133.45 | -61.43 | -167.53 | -68.82 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -7.92 | -- | -- | -- |
| Artelo Biosciences Inc | 0.00 | -10.44m | 3.62m | 5.00 | -- | 0.4953 | -- | -- | -3.33 | -3.33 | 0.00 | 2.26 | 0.00 | -- | -- | 0.00 | -82.83 | -- | -88.23 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 7.87 | -- | -- | -- |
| Cell MedX Corp | 0.00 | -142.49k | 3.66m | 0.00 | -- | -- | -- | -- | -0.0021 | -0.0021 | 0.00 | -0.0028 | 0.00 | -- | -- | -- | -190.76 | -703.78 | -- | -- | -- | 84.03 | -- | -2,996.54 | -- | -4.35 | -- | -- | -100.00 | -- | 71.22 | -- | -- | -- |
| Oncternal Therapeutics Inc | 1.85m | -35.97m | 3.69m | 27.00 | -- | 0.2342 | -- | 2.00 | -12.19 | -12.19 | 0.6254 | 5.32 | 0.0495 | -- | -- | 68,370.37 | -96.40 | -49.40 | -116.52 | -54.51 | -- | -- | -1,948.70 | -1,342.98 | -- | -- | 0.00 | -- | -47.32 | -- | 10.62 | -- | -- | -- |
| Silexion Therapeutics Corp | 0.00 | -523.87k | 3.69m | 0.00 | -- | 0.5765 | -- | -- | -0.1403 | -0.1403 | 0.00 | 0.6559 | 0.00 | -- | -- | -- | -3.13 | -- | -3.77 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -54.96 | -- | -- | -- |
| Enveric Biosciences Inc | 0.00 | -10.59m | 3.70m | 7.00 | -- | 0.6048 | -- | -- | -3.67 | -3.67 | 0.00 | 0.6862 | 0.00 | -- | -- | 0.00 | -133.67 | -104.94 | -206.10 | -156.88 | -- | -- | -- | -243.54 | -- | -- | 0.00 | -- | -- | -- | 7.14 | -- | -- | -- |
| Bone Biologics Corp | 0.00 | -5.12m | 3.73m | 2.00 | -- | 0.805 | -- | -- | -10.26 | -10.26 | 0.00 | 2.21 | 0.00 | -- | -- | 0.00 | -94.66 | -98.31 | -119.03 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -502.76 | -- | -- | -- |
Data as of Oct 09 2024. Currency figures normalised to Theriva Biologics Inc's reporting currency: US Dollar USD
4.66%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 31 Mar 2024 | 225.27k | 1.30% |
| BlackRock Fund Advisorsas of 31 Mar 2024 | 189.18k | 1.10% |
| Geode Capital Management LLCas of 30 Jun 2024 | 141.17k | 0.82% |
| Renaissance Technologies LLCas of 30 Jun 2024 | 103.71k | 0.60% |
| SSgA Funds Management, Inc.as of 31 Mar 2024 | 48.69k | 0.28% |
| Northern Trust Investments, Inc.(Investment Management)as of 31 Mar 2024 | 26.60k | 0.15% |
| Citadel Securities LLCas of 31 Mar 2024 | 24.68k | 0.14% |
| Two Sigma Securities LLCas of 31 Mar 2024 | 21.27k | 0.12% |
| Charles Schwab Investment Management, Inc.as of 31 Mar 2024 | 13.57k | 0.08% |
| SageView Advisory Group LLCas of 31 Mar 2024 | 10.43k | 0.06% |
More ▼
Data from 31 Mar 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
